Connect with us

Health

Trump Administration Begins Layoffs at CDC, FDA and Other Health Agencies

Published

on

Trump Administration Begins Layoffs at CDC, FDA and Other Health Agencies

The Trump administration laid off thousands of federal health workers on Tuesday in a purge that included senior leaders and top scientists charged with regulating food and drugs, protecting Americans from disease and researching new treatments and cures.

Layoff notices began arriving at 5 a.m., workers said, affecting offices responsible for everything from global health to food safety. Senior officials based in the Washington area and Atlanta were reassigned to the Indian Health Service and asked to choose among locations including Alaska, Oklahoma and New Mexico — a tactic to force people out, employees said.

The layoffs and reassignments touch every aspect of the federal Department of Health and Human Services, and are part of what the administration has said is a vast restructuring of the agency. Entire units focused on reproductive health and preventing gun injuries were wiped out. So was a vaccine research program aimed at preventing the next pandemic.

On Tuesday afternoon, Senator Bill Cassidy, Republican of Louisiana and chairman of the Senate health committee, summoned Health Secretary Robert F. Kennedy Jr. to testify about the agency reorganization at a hearing on April 10.

Outside experts and former officials said the loss of expertise was immeasurable. Many described it as a “bloodletting.” Hundreds of people, many carrying handmade signs, gathered in the lobby of a National Cancer Institute building in the Maryland suburbs on Tuesday morning to witness the exodus of fired workers, but were dispersed so they could walk out without fanfare. Some employees, both current and former, were in tears.

Advertisement

But as staff members reeled and comforted one another, Mr. Kennedy posted a video on social media that showed him swearing in the new heads of the Food and Drug Administration, Dr. Martin A. Makary, and the National Institutes of Health, Dr. Jay Bhattacharya.

“Welcome aboard,” Mr. Kennedy said. “The revolution begins today.”

The cuts were intended to fulfill Mr. Kennedy’s plan, announced last week, to shrink his department from 82,000 to 62,000 employees. Tuesday’s layoffs affected 10,000 employees, on top of 10,000 who had already been fired or left voluntarily. The department did not respond to a request for comment on the record.

The restructuring is intended to bring communications and other functions directly under Mr. Kennedy, who has vowed to “make America healthy again.” It includes collapsing a number of agencies into a new division called the Administration for a Healthy America. Mr. Kennedy said last week that the department was “going to do more with less.”

Jessica C. Henry, 40, said she had been fired along with her entire team of communications and health education specialists at the National Institute of Dental and Craniofacial Research, a small branch of the National Institutes of Health with a budget of about $500 million. Their work focused on educating people about childhood dental health, including birth defects like cleft lips and palate, as well as water fluoridation and instructions on oral health maintenance as an aging adult.

Advertisement

Ms. Henry said she logged into her computer at her desk at N.I.H. headquarters in Maryland around 7 a.m., only to see an email notifying her of her termination.

“I also just feel so confused, and honestly kind of angry, because we hear a lot about how the administration wants to increase transparency,” she said in an emotional interview. “They want accountability to the American people for how their tax dollars are being spent. And from what I can tell, they just fired all of us who do that.”

Layoff notices began arriving at 5 a.m., workers said, affecting offices responsible for everything from global health to medical devices to communications at agencies including the F.D.A., the N.I.H. and the Centers for Disease Control and Prevention.

Mr. Kennedy is also eliminating entire but lesser known parts of his department, such as the Administration for Community Living, which supports programs that help older Americans and people with disabilities live independently. Advocates for disability rights say the cuts could deprive the most vulnerable Americans of housing, personal care and other services.

At the Substance Abuse and Mental Health Services Administration, cuts hollowed out entire offices including the internal policy lab, the team that administers a national survey of drug use, an office of behavioral health equity, the contracts management division and all 10 regional offices, according to Miriam Delphin-Rittmon, the former assistant health secretary for mental health and substance use. She left the agency on Jan. 20 and has been hearing from former colleagues.

Advertisement

The policy lab was established as part of the 21st Century Cures Act, a law passed by Congress in 2016.

“It’s not clear really the strategy,” Ms. Delphin-Rittmon said. “Those are important content areas.”

The cuts also fell on senior leaders, including the director of the center for mental health services, Dr. Anita Everett, who was hired into a senior position at the agency during the first Trump administration, and Michelle Greenhalgh, the agency’s director of legislative affairs, according to multiple people with direct knowledge of the filings.

“Today was simply a tragedy,” said Michael T. Osterholm, who directs the University of Minnesota’s Center for Infectious Disease Research and Policy, and has advised presidents of both parties. “There is so much intellectual capital that literally got swept under the rug today in this country, and we are going to pay a price for this for years to come.”

Dr. Bhattacharya, on his first day of work, sent an email to staff saying the layoffs would “have a profound impact on key N.I.H. administrative functions, including communications, legislative affairs, procurement and human resources.” He expressed his appreciation for the “scientists and staff whose work has contributed to lifesaving breakthroughs in biology and medicine.”

Advertisement

A number of top health officials received notice that they were being reassigned to regional offices of the Indian Health Service, which is responsible for providing federal health services to Native Americans and Alaska Natives.

At N.I.H., several institute directors — including Dr. Jeanne Marrazzo, head of the National Institute of Allergy and Infectious Diseases, the institute formerly led by Dr. Anthony S. Fauci — were reassigned. So were Dr. Fauci’s wife, Christine Grady, the head of the N.I.H. Office of Bioethics, and Dr. Clifford Lane, a close ally of Dr. Fauci’s who oversaw clinical research.

At the F.D.A., the top tobacco regulator, Brian King, was reassigned. At the C.D.C., several leaders, including Kayla Laserson, who ran the global health center, also were reassigned to the Indian Health Service.

The health service is chronically understaffed and underfunded; the reassignment notices said it has an “untenable vacancy rate” of 30 percent. Mr. Kennedy recently lamented that it has been “treated as the redheaded stepchild at H.H.S.” and said President Trump wants him to “rectify this sad history.”

Those who received the reassignments were given until Wednesday to decide whether to accept the offer, or leave their jobs.

Advertisement

Some workers knew that they would be affected by the layoffs. At the department headquarters in Washington, officials responsible for minority health and infectious disease prevention were told Friday that their offices were being eliminated, according to employees.

Others were caught off guard. At the F.D.A., senior leaders were pushed out and offices focused on food, drug and medical device policy were hit with deep staff reductions amounting to about 3,500 agency staff members. On Friday, the agency’s top vaccine regulator, Dr. Peter Marks, was forced to resign under pressure. He lashed out at Mr. Kennedy afterward, saying the secretary “doesn’t care about the truth.”

Some F.D.A. workers said that they discovered they had been fired when they attempted to scan their badges to get into the building early Tuesday. The office of the center director for veterinary medicine was wiped out, according to a person familiar with the cuts. That included veterinarians leading bird flu response for the agency.

Employees of several F.D.A. labs around the United States were also let go, including those who test medical products in Detroit and San Juan, Puerto Rico, and those who test food in San Francisco and Chicago.

“The F.D.A. as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed,” Dr. Robert Califf, who ran the Food and Drug Administration during the Biden administration, wrote on social media. He said “history will see this” as “a huge mistake.”

Advertisement

At the C.D.C., which Mr. Kennedy wants to pare back to focus only on infectious disease, the reorganization is likely to have immediate effects. Offices devoted to the study of other programs, including reproductive health, chronic disease and gun violence prevention, were disbanded.

The administration has eliminated offices dedicated to protecting workers in various industries, including those that inspect mines for safety. A two-year project to study the effects of radiation was eliminated, as was an ongoing project on lead contamination in Milwaukee.

“These cuts to agency experts and programs leave our country less safe, less prepared and without the necessary talent and resources to respond to health threats,” Dr. Mandy Cohen, who led the Centers for Disease Control and Prevention during the Biden administration, said in a text message.

Some infectious disease teams were also laid off. A group focused on improving access to vaccines among underserved communities was cut, as was a group of global health researchers who were working on preventing transmission of H.I.V. from mother to child.

H.I.V. prevention was a big target overall. The Trump administration had been weighing moving the C.D.C.’s division of H.I.V. prevention to a different agency within the health department. But on Tuesday, teams leading H.I.V. surveillance and research within that division were laid off. It was unclear whether some of those functions would be recreated elsewhere.

Advertisement

Employees laid off at the agency included those studying injuries, asthma, lead poisoning, smoking and radiation damage, as well as those that assess the health effects of extreme heat and wildfires.

Communications offices were hit particularly hard across agencies including the N.I.H., C.D.C. and F.D.A. Renate Myles, the communications director at the National Institutes of Health, received a notice of reassignment. At the C.D.C., specialists in tuberculosis communications and education were laid off.

Mr. Kennedy, who promised “radical transparency,” has said he wants to consolidate communications under his purview.

The H.H.S. “is centralizing communications across the department to ensure a more coordinated and effective response to public health challenges, ultimately benefiting the American taxpayer,” Emily Hilliard, deputy press secretary for the department, said in an email on Friday.

But other divisions responsible for providing the public with information were hit, too.

Advertisement

The team that responds to Freedom of Information Act requests at the C.D.C. was eliminated, and a similar team at the F.D.A. was deeply cut, according to sources familiar with each office. They spoke on condition of anonymity out of fear of reprisal.

Processing such requests is required by law, but can be a painstaking process, given rules requiring the redaction of information such as a company’s trade secrets.

Benjamin Mueller, Gina Kolata, Aishvarya Kavi and Margot Sanger-Katz contributed reporting.

Health

Experimental obesity drug outperforms traditional weight-loss treatments in early research

Published

on

Experimental obesity drug outperforms traditional weight-loss treatments in early research

NEWYou can now listen to Fox News articles!

A new weight-loss drug variation is showing promise in early trials.

Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani.

The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity, inflammation, fat metabolism and liver health.

‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS

Advertisement

The team of researchers, led by Professor Timo D. Muller at Helmoltz Munich, called the drug a quintuple agonist, as it targets five receptor systems.

In a press release, Muller described the drug as a “Trojan horse”: the incretin component — hormones that help regulate blood sugar and appetite — allows it to enter target cells, and once inside, the PPAR “cargo” activates to help the body better use insulin, process fat and reduce inflammation.

The researchers hope the “Trojan horse” effect will allow for lower dosing and fewer side effects. (iStock)

This allows for the dosage of the drug to be lower, which could reduce side effects.

“A major advantage is the amount,” Muller said. “Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower.”

Advertisement

NEW WEIGHT-LOSS SHOT SHOWS MAJOR FAT REDUCTION, BUT EXPERTS URGE CAUTION

The study tested the drug combination in mouse models, including mice with diabetes-induced obesity, insulin resistance and genetic obesity.

In these mice, the compound was found to lower body weight, food intake, fat mass, blood sugar and insulin-related problems more than GLP-1 and GIP alone. It also outperformed semaglutide.

CLICK HERE FOR MORE HEALTH STORIES

The researchers reported that typical gastrointestinal side effects were similar to those seen with existing therapies.

Advertisement

“We see a principle with strong effects in the animal model — now the task is to optimize the approach for humans and move it toward the clinic,” Muller said in the release.

The preclinical study was conducted in mouse models and cannot yet be applied to humans. (iStock)

Dr. Peter Balazs, MD, a hormone and weight-loss specialist practicing in New York and New Jersey, said the drug is designed to target obesity and insulin resistance “at multiple key sites simultaneously, including the brain, pancreas and metabolic tissues.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“This is a novel mechanism because it’s not just relying on a higher dose of an existing drug,” he told Fox News Digital in an interview.

Advertisement

“Current GLP-1 medications are highly effective appetite suppressants, while this quintuple agonist seems to function both as an ‘appetite brake’ and a metabolic engine,” he added.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above” while also “directly improving insulin sensitivity in the liver and muscle, reducing inflammation in adipose tissue and remodeling lipid metabolism,” the expert confirmed.

While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above,” an expert said. (iStock)

“The result may be greater weight loss through a combination of caloric restriction, enhanced fat oxidation and potentially increased central energy expenditure,” Balazs said.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Although the drug provides a “promising direction for the future,” Balazs noted that the study was conducted only on mouse models and there is no human safety or efficacy data, which means the drug cannot yet be recommended for clinical use.

“Additionally, it was conducted over a relatively short period of time, so we cannot draw conclusions about long-term effects,” he added.

Continue Reading

Health

With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win

Published

on

With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win

Over lunch at his golf club in Jupiter, Fla., on the first Saturday of May, President Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.

Eventually Mr. Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the F.D.A. commissioner.

No answer.

Furious, the president then dialed Dr. Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the F.D.A.’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.

The message was received. Less than one week later, the executives got what they wanted.

Advertisement

On Friday, the F.D.A. issued new guidance that could pave the way for major tobacco companies to begin selling flavored vapes and to snare a chunk of the $6 billion e-cigarette market away from illegal Chinese competitors. The new policy bypassed the F.D.A.’s regular rule-making process.

In the intervening week, Dr. Makary continued to argue against approving flavored vapes as support from Mr. Kennedy and others collapsed around him. Health and Human Services Department staff began to draft the new plan, according to two people familiar with the events.

On Tuesday, Dr. Makary resigned, telling associates he could not in good conscience remain the head of an agency that backed such a policy.

Though there is no definitive evidence linking the new guidance to donations or lobbying, the episode represented a clear pivot in the federal government’s longtime approach to the tobacco industry.

Since the 1990s, when states extracted vast payments and other concessions from the major cigarette companies in a nationwide legal settlement, Big Tobacco has been in retreat. Cigarette sales have plummeted, and regulations have mounted as consumers and administrations from both parties embraced public health consensus about the dangers of smoking and nicotine addiction.

Advertisement

Mr. Trump’s first administration initially continued the trend, proposing further restrictions on cigarettes and moving to outlaw flavored vapes over concerns that their rising popularity threatened the health of a generation of adolescents.

But since then, Mr. Trump has enthusiastically welcomed the financial support of the tobacco industry and has courted e-cigarette users as a political constituency.

The new vaping guidance highlights Mr. Trump’s willingness to use his executive authority to prioritize the causes of major corporate donors over public health concerns, taxpayer interests and the judgment of experts, sometimes including those in his own administration.

The president has developed a close relationship with tobacco companies including Altria and Reynolds American, which have donated millions of dollars to his political groups and projects, including his proposed White House ballroom. Their executives attended the lunch at the president’s golf club.

The Department of Health and Human Services, which oversees the F.D.A., referred requests for comment to the White House.

Advertisement

Kush Desai, a White House spokesman, said in a statement that Mr. Trump has pushed to expand access to vapes to help Americans trying to quit smoking.

“The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Mr. Desai said.

Reynolds American and Altria did not respond to questions about their lobbying or the conversation at the lunch.

It was attended by Jeff Raborn, a top executive at Reynolds, and Phil Park and Todd Walker of Altria, according to the people familiar with the meeting. Also attending were Brian Ballard and Rich Haselwood, lobbyists for the firm Ballard Partners, which represents Reynolds and helped marshal a sophisticated and expensive influence campaign that culminated in the new vaping guidance. Mr. Ballard is a top fund-raiser for Mr. Trump. Mr. Haselwood had been an in-house lobbyist at Reynolds before joining Ballard Partners this year.

A spokesman for Ballard Partners declined to comment.

Advertisement

While public health experts consider e-cigarettes a less harmful alternative to tobacco-burning cigarettes, the new guidance circumvents a scientific review process the F.D.A. had previously defended up to the Supreme Court. The disregarded procedures were meant to ensure approval of only those products shown in studies to help cigarette smokers transition to vapes without attracting a new generation of nicotine users.

The guidance also could allow higher nicotine levels in nicotine pouches. It includes a pledge to prioritize efforts to stop the import of illegal foreign vapes, an idea that has bipartisan support in Congress.

Taken together, the policy changes could help companies like Altria and Reynolds gain market share considered central to the survival of the industry.

The market for vapes and nicotine pouches, like Zyn, is about 30 million people in the United States, on par with the number of cigarette smokers. While the nicotine pouch market is rapidly growing, cigarettes still account for about $50.8 billion, or nearly 70 percent of the annual tobacco sales in the United States, according to a Goldman Sachs research report. Vape sales have lagged amid competition from illicit products.

In recent years, the F.D.A. has moved glacially to approve e-cigarettes, authorizing only those in tobacco or menthol flavors, including some sold by Reynolds and Altria. Unapproved Chinese vapes have poured into the United States, feeding a thriving illicit market with flavors like peach slush and watermelon ice. Last year, industry executives have said, illicit fruit-flavored vapes made up 60 percent of the e-cigarette market.

Advertisement

When Mr. Trump mounted his bid to return to the White House, some in the tobacco industry went all in, hoping he would loosen regulations on vapes and abandon plans by the Biden administration to ban menthol cigarettes and crack down on other cigarette sales.

Mr. Trump in some ways makes for an unlikely savior for the tobacco industry. He has never smoked, but he pledged during his 2024 campaign to “save vaping again.”

Through a subsidiary, Reynolds, which is the biggest seller of menthol cigarettes, donated $10 million to a super PAC backing Mr. Trump’s campaign, according to campaign finance filings. There is no public record of the subsidiary donating to groups supporting Mr. Biden or the campaign of former Vice President Kamala Harris.

Mr. Ballard, whose firm has been paid more than $4.4 million by Reynolds since the beginning of 2017, arranged for Mr. Trump to have dinner during the campaign with Reynolds executives in New York, according to a person familiar with the interactions. The executives urged Mr. Trump to oppose the menthol cigarette ban and expressed concern about Chinese vapes.

Reynolds executives including Mr. Raborn and Mr. Haselwood were such a presence around the campaign that Mr. Trump took to calling them “my tobacco guys,” according to the person familiar with the interactions and a book coauthored by a New York Times reporter and published last year.

Advertisement

When Mr. Trump won, the rest of the industry jockeyed to show support.

Altria donated $1 million to his inaugural committee; the Vapor Technology Association donated $1.25 million; and a subsidiary of Philip Morris donated $500,000.

On Mr. Trump’s second full day in office, his administration withdrew the proposed ban on menthol cigarettes, an initiative the Biden administration had already mostly abandoned. Mr. Trump’s team also set aside a Biden-era proposal to sharply restrict nicotine in cigarettes, an effort meant to speed the transition away from a product known to be deadly.

In applauding the withdrawal of the menthol ban, Billy Gifford, the chief executive of Altria, told investors on an April 2025 earnings call that “we’re hopeful that that activity and momentum continues.”

The courtship intensified.

Advertisement

Reynolds pitched in another $3 million to a different Trump-backed super PAC, while Altria and Juul each donated $1 million.

And Reynolds and Altria each donated to the effort to raise private funds to build a new White House ballroom. Mr. Raborn of Reynolds and Mr. Walker of Altria were invited to a dinner at the White House in October for donors who gave $2.5 million or more, as was Mr. Ballard.

Tadeu Marroco, the chief executive of British American Tobacco, which owns Reynolds American, predicted to investors earlier this year that the Trump administration would clamp down on illegal vapes, saying “it’s very encouraging, the signs that the new administration is giving to address that.”

The companies’ lobbying strategy also has reached into the states, where they are pushing for so-called “registry laws” — of which there are now more than a dozen including in Florida, Virginia and Pennsylvania. Many of those laws restrict e-cigarette sales to only vapes on a list from the F.D.A.

The guidance released last week said it would create such a list.

Advertisement

Sheryl Gay Stolberg contributed reporting.

Continue Reading

Health

First clade I mpox case confirmed in Connecticut after patient traveled to Western Europe

Published

on

First clade I mpox case confirmed in Connecticut after patient traveled to Western Europe

NEWYou can now listen to Fox News articles!

A case of clade I mpox — a more virulent version of the virus that causes monkeypox, according to the Centers of Disease Control and Prevention (CDC) — has been confirmed in the U.S., as global health officials also monitor newly reported hantavirus cases in Europe.

The Connecticut Department of Public Health (CDPH) said Wednesday that the state’s first identified case of clade I mpox was detected in a person who recently traveled to Western Europe, where officials continue to monitor infectious disease activity.

The World Health Organization (WHO) has also reported new hantavirus cases in Spain and France, drawing attention to the rare but potentially severe disease, which can cause serious respiratory complications in humans.

Hantavirus is typically spread through contact with infected rodents and can lead to severe respiratory illness, though cases remain rare, according to the WHO.

Advertisement

While health officials said the mpox case “does not pose a risk to the general public,” they still encourage those who may be at risk to receive the JYNNEOS vaccine.

NEW MPOX STRAIN CONFIRMED IN US STATE FOR FIRST TIME

A pharmacist wearing a latex glove holds a photo of the mpox virus, which can spread through close, intimate contact with an infected person. (iStock)

Mpox symptoms can include fever, swollen lymph nodes and a characteristic rash, according to CDC.

“Mpox hasn’t gone away, and we want people to be protected, especially as many in our community prepare for travel, festivals, and gatherings this summer,” CDPH Commissioner Dr. Manisha Juthani said in the release.

Advertisement

“The vaccine is safe, effective and widely available. Completing the two-dose series is the best way to protect yourself and your partners.”

HANTAVIRUS DEATHS ON CRUISE SHIP HIGHLIGHT DANGERS OF RODENT-BORNE DISEASE

Clade I mpox, a newer strain of the virus, first appeared in California in November 2024. (iStock)

Clade I and clade II mpox are genetically distinct forms of the virus with key differences in severity and geographic origin, according to the CDC and the WHO.

Clade I, historically identified in Central Africa, has been linked to more severe illness and higher mortality rates, with cases often involving more widespread rashes and complications.

Advertisement

A traveler walks past a sign in a busy airport about mpox. (Yasuyoshi Chiba/AFP)

Clade II, which has circulated primarily in West Africa, is generally associated with milder disease and drove the global outbreak beginning in 2022, when most patients experienced less severe symptoms and lower hospitalization and death rates, according to the WHO.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The CDC and WHO say distinguishing between the two clades helps guide risk assessments, particularly as international travel increases.

Advertisement
Continue Reading
Advertisement

Trending